Study of dupilumab for young children with eosinophilic esophagitis
Treatments studied
Part of Blood & lymphatic, Digestive system, Immune system & allergy clinical trials.
This trial tests if dupilumab can help young children with eosinophilic esophagitis (EoE), a condition that causes swelling in the esophagus. It may reduce symptoms and improve how the esophagus heals.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 6 months and under 15 kilograms (about 33 pounds) and has active EoE.
- Your child has had symptoms caused by EoE in the last month, as decided by the study doctor.
- A biopsy during screening shows high levels of a certain white blood cell (eosinophil) in at least 2 areas of the esophagus.
- Your child has not taken dupilumab before, and has not used swallowed steroid treatments in the past 8 weeks.
- Your child does not have other conditions like Crohn's disease, celiac disease, or a current Helicobacter pylori infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two medicines—Eohilia (an oral steroid) and Dupixent (an injectable biologic)—to see which one better helps widen the esophagus in people with eosinophilic esophagitis (EoE). It may help you if you have active EoE and are looking for a new treatment option.
This trial tests if dupilumab, a weekly injection, can improve the muscle function of the esophagus in people with eosinophilic esophagitis (EoE) who haven't gotten better with acid-reducing medications. Researchers want to see if it helps with swallowing and reduces inflammation.
This study looks at how the immune system and the esophageal barrier function in people with eosinophilic esophagitis (EoE) compared to those without. It involves taking biopsies during an upper endoscopy to understand the disease better. The results may help improve treatments for EoE.
This study tests if the medicine Dupilumab can help control asthma and wheezing in children ages 2 to just under 6. It is for children whose symptoms are not well-managed with their current inhaler.
This study looks at how well Dupilumab works over time in people aged 12 and older with eosinophilic esophagitis (EoE) whose symptoms are not well controlled by standard treatments. It aims to understand the medicine's effects in everyday medical practice.
This study compares two treatments for EoE that has caused narrowing in the esophagus: dupilumab (a biologic injection) versus a topical corticosteroid (a swallowed steroid). It aims to see which works better for teens and young adults to improve swallowing and reduce inflammation.
Hear when a new Eosinophilic Esophagitis (EoE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.